GlassScriptPhysician profile
Melissa Lamirand
NPI 1346706371
$68,163.83
in general payments reported to CMS, 2019-2025
7 companies · $23K in 2025
The $23K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $118 · 2022: $313 · 2023: $23K · 2024: $22K · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $46K · Travel and Lodging: $18K · Food and Beverage: $2,972 · Consulting Fee: $740.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $45,750.00 |
| Travel and Lodging | $18,272.03 |
| Food and Beverage | $2,971.65 |
| Consulting Fee | $740.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $66,889.90 | 2021-2025 | |
| Glaxosmithkline, LLC. | $747.67 | 2022-2025 | |
| Karyopharm Therapeutics INC. | $220.08 | 2022-2023 | Xpovio |
| Acadia Pharmaceuticals INC | $111.25 | 2024 | Nuplazid |
| Janssen Scientific Affairs, LLC | $90.00 | 2024 | Talvey |
| Y-Mabs Therapeutics, INC. | $85.07 | 2022 | |
| Celgene Corporation | $19.86 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Lamirand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.